Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Subject: Schizophrenia - PUBLISHED VIA Brazilian Journal of Medical and Biological Research

Author(s):
Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS

Departamento de Neurologia, Psiquiatria e Psicologia Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. awzuardi@fmrp.usp.br

 View Source >>

Related Studies:

Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

Published via Drug Testing and Analysis

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Published via Translational Psychiatry

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Published via Current Pharmaceutical Design

Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Published via Neuropsychopharmacology

Cannabidiol as a potential treatment for psychosis.

Published via European Neuropsychopharmacology

View all medical studies

Learn More About Cannabis

Website & branding by the Ganjapreneur in-house agency:

Blue Dream - Uplifted cannabis industry branding & marketing.

Uplifted cannabis industry branding & marketing.